Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regression
Lucia Poncette, … , Felix K.M. Lorenz, Thomas Blankenstein
Lucia Poncette, … , Felix K.M. Lorenz, Thomas Blankenstein
Published December 10, 2018
Citation Information: J Clin Invest. 2019;129(1):324-335. https://doi.org/10.1172/JCI120391.
View: Text | PDF
Research Article Immunology Oncology

Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regression

  • Text
  • PDF
Abstract

Adoptive transfer of T cell receptor–engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1–reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with NY-ESO-1–redirected CD8+ T cells in a mouse model of adoptive T cell therapy. These data suggest that MHC II–restricted TCRs against NY-ESO-1 from a nontolerant nonhuman host are of optimal affinity and that the combined use of MHC I– and II–restricted TCRs against NY-ESO-1 can make adoptive T cell therapy more effective.

Authors

Lucia Poncette, Xiaojing Chen, Felix K.M. Lorenz, Thomas Blankenstein

×

Figure 1

NY-ESO-1–reactive TCRs generated from ABabDR4 mice.

Options: View larger image (or click on image) Download as PowerPoint
NY-ESO-1–reactive TCRs generated from ABabDR4 mice.
(A) PBLs from an ABa...
(A) PBLs from an ABabDR4 mouse immunized with NY-ESO-1116 peptide or NY-ESO-1 DNA were pulsed with NY-ESO-1116 or irrelevant peptide and were stained intracellularly after overnight incubation. The results shown are representative of >10 (Peptide imm.) and 3 (DNA imm.) mice. (B) For sorting by flow cytometry, NY-ESO-1–reactive CD4+ T cells were labeled by the IFN-γ capture method following NY-ESO-1116 restimulation (TCR-3598/3598_2) or by DR4/NY-ESO-1116 tetramer staining following a 1-week culture period in the presence of 10–8 M NY-ESO-1116 (TCR-3600 and -5712) or αCD3/CD28 beads (TCR-5713). (C) Splenocytes from an ABabDR4 mouse immunized with NY-ESO-1 DNA were pulsed with NY-ESO-1116 or irrelevant peptide and stained intracellularly after 6 hours of incubation. (D) Human CD4+ T cells were transduced with NY-ESO-1–reactive TCRs isolated from CD4+ T cells shown in B and stained with DR4/NY-ESO-1116 tetramer and for mouse TCRβ constant region (mTCRβ). α and β sequences of NY-ESO-1–reactive TCRs are listed in Table 1. Plotted cells were gated on lymphocytes, live cells, and CD3+ cells (A and B), and CD4+ cells (C and D). Results are representative of 2 independent experiments (C and D). Values represent percentages. See also Supplemental Figure 1.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts